Targanta’s Oritavancin Gets FDA “Complete Response”; Additional Phase III Needed
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency requests Phase III study with MRSA subgroup: cost of additional study could lead company to seek development partner.